Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Repurposing monoclonal antibodies in the face of the COVID-19 pandemic

Christian Chabannon • 1 Sep 2020
EBMT 2020
General Antibodies Tocilizumab

Christian Chabannon, MD, PhD, Aix Marseille University (AMU) School of Medicine, Marseille, France, discusses the repurposing of monoclonal antibodies and other immunotherapies during the COVID-19, with the aim of modulating the hyper-immune response associated with the disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Sanofi SA, Kite / Gilead, Novartis, Celgene / BMS, Janssen, Bellicum Pharmaceuticals, Terumo BCT: speakers bureau & advisory boards

More from Christian Chabannon

1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024
1:33
Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies
Christian Chabannon • 17 Feb 2024
1:36
IFM-2015-03: plerixafor before salvage ASCT in R/R myeloma
Christian Chabannon • 21 Oct 2023

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals